An ongoing dialogue on HIV/AIDS, infectious diseases,
June 13th, 2011
More on Generic Antiretrovirals …
In the recent post on the approval of generic Combivir — and the lack of availability of generic Epivir (lamivudine, 3TC), which was both anticipated and likely to be more useful — I speculated there were several possible causes of this surprising turn of events.
But ultimately I concluded, “In sum, the real reason there’s no generic 3TC remains a mystery.”
Last week, however, I received a fascinating email from an industry representative, who has asked that I summarize the turn of events from their perspective:
- The Epivir patent in the US expired in May 2010.
- A generic company was granted exclusive rights to market a generic in the US for 6 months. (This is part of patent law.)
- The particular company that was granted exclusivity was not been able to manufacture a product that has met approvability standards by the FDA.
- During the period of exclusivity, furthermore, no other company can market a generic either — again, patent law in action.
Mystery solved — and thank you for the clarification.
But I hasten to add that this information was not widely known by HIV/ID specialists, and furthermore not easy to find. One of my colleagues has likened reading rulings on patent law for generics akin to learning English as a second language, a very apt analogy.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- The Paperwork Demands for Academic Medical Teaching Are OUT OF CONTROL
- Long-Acting Injectable HIV Therapy for People Who Won’t Take ART?
- More on Relapses after Paxlovid Treatment for COVID-19
- Mayo Clinic Study on Paxlovid Outcomes is Reassuring — but Likely Underestimates Rebound Rate
- Should We Prescribe Nirmatrelvir/r (Paxlovid) to Low-Risk COVID-19 Patients?
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- BNT162b2 Vaccine Effectiveness Against Omicron in Children Aged 5–11 Years
- Observations from ID and Beyond: Long-Acting Injectable HIV Therapy for People Who Won't Take ART?
- Benefits of Screening for Serum Cryptococcal Antigen in Patients with HIV-1 Infection
- Next-Generation Monoclonal Antibodies: Another Promising Approach to Malaria Prevention
- Cause of Recent Pediatric Acute Hepatitis Cases Remains Elusive
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff COVID-19 CROI cure darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster